Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01266811Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2011
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Siltuximab + Velcade + Dex with Placebo + Velcade + Dex (2 arms). Primary endpoint: Progression-Free Survival up to 5 years. Planned start Jul 2011; status: withdrawn.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01266811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266811.